Ready to be part of something bigger? Sirtex Medical is entering a new era of growth following the FDA approval of SIR-Spheres® Y-90 resin microspheres for hepatocellular carcinoma (HCC). This breakthrough expands our impact in the fight against liver cancer and makes SIR-Spheres® the first and only Y-90 radioembolization therapy in the U.S. approved to treat both HCC and metastatic colorectal cancer to the liver. It’s a milestone that reinforces our leadership in interventional oncology and creates new opportunities for you to make a difference.
With this milestone, Sirtex is expanding its reach in various geographies across the nation! We’re delivering our therapy to more patients, enabling more physicians to make a difference, and elevating the global standard of care for those affected by liver cancer.
We are a global healthcare company with offices in Boston, Sydney, Frankfurt, and Singapore, dedicated to developing minimally invasive cancer treatments that extend and improve lives. To date, we have delivered over >150K doses of SIR-Spheres® Y-90 resin microspheres across 50+ countries, significantly impacting patients' lives worldwide.
We’re a growing organization at an exciting stage of expansion, creating new opportunities for our people to shape the future of interventional oncology. Guided by innovation, collaboration, and a commitment to improving patient lives, Sirtex offers a values-led, inclusive culture that supports creativity, continuous learning, and excellence.
Join us and be part of a team that’s shaping what’s next for patients, physicians, and the global healthcare community.
Follow
